Therapeutic antibody and uses thereof
AssigneeMultitude Therapeutics Inc.
InventorsXun Meng, Jian-Xin Bao, Bing Hou
Life of this patent
Estimating the term…
Abstract
The invention described herein provides antibodies or antigen-binding fragment thereof specific for an epitope within the variant exon v6 or v9 of the CD44 gene (CD44v6 or CD44v9), antibody-drug-conjugate (ADC) thereof, and other derivative comprising the antibodies or antigen-binding fragment thereof. The invention also provides nucleic acid molecules encoding the same, and methods of making the same. The invention further provides pharmaceutical compositions comprising the same, and the use of the same in treating diseases or in the manufacture of a medicament for the treatment of the diseases, such as cancer.
Claims26
1-9. (canceled)
An isolated monoclonal antibody, or an antigen-binding fragment thereof, specific for an isolated CD44v9 epitope, wherein said monoclonal antibody comprises:
- (1) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
- 25, a HCVR CDR2 sequence of SEQ ID NO:
- 26, and a HCVR CDR3 sequence of SEQ ID NO:
- 27;
- (2) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
- 34, a LCVR CDR2 sequence of RMS, and a LCVR CDR3 sequence of SEQ ID NO:
- 36.
11-14. (canceled)
19-20. (canceled)
22-23. (canceled)
25-26. (canceled)
28-33. (canceled)
35-52. (canceled)
54-63. (canceled)
65-68. (canceled)
70-76. (canceled)
A method for treating a subject having cancer, wherein cells of the cancer expresses CD44v9, or treating a cell-proliferative disorder in a subject, wherein cells of the cell-proliferative disorder expresses CD44v9, the method comprising administering to said subject a therapeutically effective amount of an antagonist of CD44v9 comprising a CD44v9 antibody or an antigen-binding fragment thereof.
78-81. (canceled)
83-84. (canceled)
Dependencies are inferred from the claim text.